Watson to invest $44 million in R&D and manufacturing plant expansion

23 June 2011

US branded and generics drugmaker Watson Pharmaceuticals (NYSE: WPI) says it is investing around $44 million in the expansion of its Salt Lake City, Utah, Watson Laboratories site. This facility is Watson's state-of-the-art pharmaceutical research, development and manufacturing facility for transdermal patches and topical gels.

The Salt Lake City expansion includes retrofitting about 20,000 square feet of existing space and the construction of approximately 17,000 square feet of future manufacturing space. The company anticipates the expansion could ultimately result in the addition of approximately 300 employees within the next three to five years.

Plans generic Lidoderm launch next year

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK